Figure 7.

OSU-53 reduces MDSC frequency in tumor-bearing mice. Female Balb/c mice were inoculated with EMT-6-HER2 breast cancer cells in the mammary fat pad. The mice received OSU-53 (100 mg/kg) or vehicle via oral gavage for a period of 2 weeks. (A) Tumor growth in mice treated with OSU-53 or vehicle. (B) Weight of spleens from mice (C–D) FACS analysis of splenocytes and single cell suspensions prepared from tumors stained with CD11b and Gr1 and antibodies. Each group consisted of five mice. Values are the mean ± SE of tumor volumes at each time point, (p < 0.05).